You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Effectively Managing KRAS-Mutated Non-Small Cell Lung Cancer: Translating Evidence Into Practice

  • Authors: Ferdinandos Skoulidis, MD, PhD
  • CME / ABIM MOC Released: 12/13/2021
  • Valid for credit through: 12/13/2022, 11:59 PM EST
Start Activity

Target Audience and Goal Statement

This activity is intended for oncologists, pulmonologists, and pathologists.

The goal of this activity is to improve clinicians' skill in using precision medicine approaches to manage patients with KRAS-mutated non-small cell lung cancer (NSCLC).

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical trial data on targeted therapies being evaluated to manage patients with KRAS-mutated NSCLC
  • Have greater competence related to
    • Identifying which molecular tests to administer to guide treatment for KRAS-mutated NSCLC
    • Selecting treatment guided by molecular test results in a patient with KRAS-mutated NSCLC
    • Managing treatment-related adverse events in patients receiving targeted therapy for KRAS-mutated NSCLC


As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


  • Ferdinandos Skoulidis, MD, PhD

    Assistant Professor
    Department of Thoracic/Head and Neck Medical Oncology
    Division of Cancer Medicine
    The University of Texas MD Anderson Cancer Center
    Houston, Texas​ 


    Disclosure: Ferdinandos Skoulidis, MD, PhD, has the following relevant financial relationships:
    Advisor or consultant for: Amgen Inc.; Beigene; Intellisphere LLC; Navire Pharma
    Speaker or a member of a speakers bureau for: Bristol Myers Squibb; RV Mais Promocao Eventos LTDS
    Grants for clinical research from: Amgen Inc.; Boehringer Ingelheim; Merck & Co; Mirati Therapeutics; Novartis; Pfizer
    Stocks, stock options, or bonds from: BioNTech SE; Moderna Inc.
    Ownership of an ineligible company: BioNTech SE; Moderna Inc.
    Other: Travel expenses for Tango Therapeutics; Food and Beverage Expenses for Amgen Inc. and AstraZeneca Pharmaceuticals​​


  • Lisa Cockrell, PhD

    Medical Education Director, Medscape, LLC


    Disclosure: Lisa Cockrell, PhD, has disclosed no relevant financial relationships.

  • Amy Furedy, RN, OCN

    Medical Education Director, Medscape, LLC


    Disclosure: Amy Furedy, RN, OCN, has disclosed no relevant financial relationships.

CME Reviewer

  • Robert Morris, PharmD

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: ViiV Healthcare
    Owns stock, stock options, or bonds from: GlaxoSmithKline

None of the nonfaculty planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements


Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Effectively Managing KRAS-Mutated Non-Small Cell Lung Cancer: Translating Evidence Into Practice

Authors: Ferdinandos Skoulidis, MD, PhDFaculty and Disclosures

CME / ABIM MOC Released: 12/13/2021

Valid for credit through: 12/13/2022, 11:59 PM EST


The following cases are modeled on the interactive grand rounds approach. The questions within the activity are designed to test your current knowledge. After each question, you will be able to see whether you answered correctly and read evidence-based information that supports the most appropriate answer choice. The questions are designed to challenge you; you will not be penalized for answering the questions incorrectly. At the end of the activity, there will be a short post-test assessment based on the material presented.


A 56-year-old white woman presented to her primary care provider with a 3-month history of cough. At presentation, she also stated that she had been experiencing increasing fatigue that was abnormal for her. She was a former smoker, having quit smoking 5 years earlier. She was otherwise very healthy, was not on any medications, and maintained a busy life and career. Given her prior smoking history, her physician ordered a chest x-ray, which revealed a small mass in her left lung. Following referral, a bronchoscopy with biopsy confirmed non-small cell lung cancer (NSCLC) with adenocarcinoma histology. An abdominal computed tomography (CT) scan showed a liver lesion, and brain metastasis was found on conventional magnetic resonance imaging (MRI). Subsequent positron emission tomography (PET)/CT revealed multiple involved lymph nodes in her abdomen.

  • Print